Deargen is a pioneering brand that revolutionizes the treatment of rare and intractable diseases by harnessing the power of artificial intelligence (AI) and collective intelligence. As an AI-First Pharmatech Company, Deargen is at the forefront of the healthcare industry, driving innovation through sequence-based drug discovery and development that bypasses the traditional reliance on 3D structure. With their cutting-edge technology, Deargen's AI platform, Dr.

UG, specializes in genome data analysis, biomarker prediction, molecule selection, and optimization, enabling the discovery of new disease targets and the design of small molecules for precision medicine. Their pipeline includes PROTAC, ADC, EPITOPE, and AGONIST INHIBITOR, offering a range of treatment strategies for various diseases. Deargen's success lies in its multidisciplinary team of experts in deep learning, software, biology, and bioinformatics.

Together, they work relentlessly to advance precision medicine, tackling new challenges with unwavering dedication. For corporate partnerships, scientific collaborations, or general inquiries, reach out to Deargen via email at contact@deargen. me or phone at +82 (0)43 716 2100.

Visit their Seoul, Daejeon, or U. S. Deargen is committed to shaping the future of healthcare through innovative AI-based solutions